Dacomitinib Beats Iressa as First Line Treatment for EGFR Mutation-Positive NSCLC [720p]

Dacomitinib Beats Iressa as First Line Treatment for EGFR Mutation-Positive NSCLC: New Option or Too Little Too Late?